Home › Research › Tau biomarkers
Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia
Shrestha S, Zhu X, Windham BG, Sullivan KJ, Palta P, Gottesman RF, Tracy RP, Jack CR et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Prospective studies of blood-based biomarkers reflecting pathogenic processes, other than Alzheimer-specific pathologies, that contribute to dementia in diverse cohorts are lacking. Methods We jointly fitted linear mixed-effect models and proportional hazards models to examine associations of midlife glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (YKL-40), soluble cluster of differentiation-14 (sCD14), neurofilament light chain (NfL), total tau (t-tau), and ubiquitin C-terminal hydrolase L1 (UCHL1) levels in serum (collected in 1993 to 1995) with cognitive decline and incident dementia (ascertained over 29 years through 2022) in the community-based Atherosclerosis Risk in Communities Study. sCD14 and YKL-40 were measured in 3082 participants and the other four biomarkers in 1766 participants. Results Higher serum GFAP, YKL-40, sCD14, and NfL were associat
What this study adds
Evidence grade: Low
The record lists 3,082 participants. In this community-based study, higher midlife serum GFAP, YKL-40, sCD14 and NfL were linked to faster cognitive decline and higher dementia rates over 29 years. These markers reflect glial dysfunction and neuronal injury rather than Alzheimer-specific pathology, and the findings are about predicting decline, not treating or preventing it.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shrestha, S., Zhu, X., Windham, B. G., Sullivan, K. J., Palta, P., Gottesman, R. F., et al. (2026). Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71422
Vancouver
Shrestha S, Zhu X, Windham BG, Sullivan KJ, Palta P, Gottesman RF, et al. Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. doi:10.1002/alz.71422. PMID: 42092335.
BibTeX
@article{shrestha2026-42092335,
author = {Shrestha, S. and Zhu, X. and Windham, B. G. and Sullivan, K. J. and Palta, P. and Gottesman, R. F. and Tracy, R. P. and Jack, C. R. and others},
title = {{Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71422},
pmid = {42092335},
url = {https://doi.org/10.1002/alz.71422}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods We jointly fitted linear mixed-effect models and proportional hazards models to examine associations of midlife glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (YKL-40), soluble cluster of differentiation-14 (sCD14), neurofilament light chain (NfL), total tau (t-tau), and ubiquitin C-terminal hydrolase L1 (UCHL1) levels in serum (collected in 1993 to 1995) with cognitive decline and incident dementia (ascertained over 29 years through 2022) in the community-based Atherosclerosis Risk in Communities Study. sCD14 and YKL-40 were measured in 3082 participants and the other four biomarkers in 1766 participants.
- Results Higher serum GFAP, YKL-40, sCD14, and NfL were associated with faster cognitive decline and elevated dementia rate (e.g., 1 standard deviation [SD] higher log-base2 YKL-40 was associated with -0.11SD faster 25-year cognitive decline (95% confidence interval [CI]: -0.15,-0.07) and 45% higher dementia hazard (hazard ratio [HR]: 1.45 [95% CI: 1.25, 1.68]).
- Higher t-tau and UCHL1 were also associated with faster cognitive decline.
- Discussion Midlife blood biomarkers reflecting glial and neuronal dysfunction and neuroinflammation are associated with early cognitive impairment.
Why it matters
In this community-based study, higher midlife serum GFAP, YKL-40, sCD14 and NfL were linked to faster cognitive decline and higher dementia rates over 29 years. These markers reflect glial dysfunction and neuronal injury rather than Alzheimer-specific pathology, and the findings are about predicting decline, not treating or preventing it.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants3,082
- Evidence strengthLow
How this study scored 41/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,082 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Myriam Fornage: h-index 3 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of North Carolina at Chapel Hill: institution h-index 1,674 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42092335) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.